





IPC

IPO

Vijaya Diagnostic Centre Limited

Issue Opens	Wednesday, Sept 01, 2021	
Issue Closes	Friday, Sept 03, 2021	
Price Band (in Rs)	522/531	
Bid Lot	28 shares and multiples thereafter	





Overview: Diagnostic Industry in India

Structure of the healthcare market:

IPO


The healthcare market in India is broadly classified into:

(i) Healthcare delivery market (hospitals) which was valued at approximately Rs4,400bn is projected to grow at a CAGR of 17-18% during FY21-FY25E.

(ii) Pharmaceuticals industry of which the domestic formulations segment was valued at approximately Rs1,420bn is projected to grow at a CAGR of 11-12% between FY21-FY25E.

(iii) Diagnostic industry which was valued at Rs710bn to Rs730bn is projected to grow at a CAGR of 14-16% between FY21-FY23E.

(iv) Healthcare insurance industry of which the health insurance premium market stood at Rs583bn as of FY21 and is expected to achieve a CAGR of 18-19% between FY21-FY25E.



Source: Company RHP

Diagnostic-Key sub-segment of Indian healthcare market:

Evidence-based treatment has become the norm for many doctors, as diagnosis enables prescription of correct therapy, and, thereby, faster recovery. Hence, in the spectrum of healthcare delivery services, diagnostic services play the key role of information intermediary, providing useful information for correct diagnosis and treatment of diseases. Diagnostic services currently have an 8-14% share in the overall healthcare spending on account of variation between rural and urban across institutions such as government-owned, charitable/trust-based and private. The diagnostic industry achieved a healthy CAGR of 13-14% from FY17-FY20, tracking the growth of healthcare delivery services. However, in FY21, CRISIL Research estimated the industry's growth rate will sharply decelerate to approximately 4% y-o-y to Rs710bn to Rs730bn, owing to the fallout of the Covid-19 pandemic. However, between FY20-FY23E, the industry is expected to return to a healthy growth trajectory of 12-13% CAGR, reaching Rs920-980bn.

SNAPSHOT			
Issue Opens	Wednesday, Sept 01, 2021		
Issue Closes	Friday, Sept 03, 2021		
Price Band (Rs)	522/531		
Bid Lot	28 shares and multiples thereafter		
Face Value	Rs1		
Listing	BSE & NSE		
Type of Issue	OFS		
	Fresh Issue	-	
Offer Size (Rs Mn)	OFS	18,950	
	Total	18,950	
*Implied Market Cap (Rs Mn)	54,144		
P/E (based on FY21 Earnings)*	63.77		

*Note: Implied Market Cap & P/E are calculated at upper price band of Rs531

Issue Allocation			
Reservations	% of Net Issue		
QIB	50		
NIB	15		
Retail	35		
Total	100		
Employee Reservation: 150,000 equity shares			

Employee Reservation: 150,000 equity shares

•

Object of the Offer

- To carry out the OFS of up to 35,688,064 equity shares by the selling shareholders
 - Achieve the benefits of listing the equity shares on the stock exchanges





Industry (contd.):

IPO


Classification of Diagnostic Industry: A. Based on Business Models:

A. based on business woulders.

Diagnostic centres in India can be classified into hospital-based, diagnostic chains, and standalone centres:

(a) Hospital-based diagnostic centres are located in hospitals for captive use. These are mostly owned by hospitals, or may be given to third parties to manage.
(b) Diagnostic chains are owned diagnostic centres, with two or more centres. These mostly operate through a hub-and-spoke model of collection centres.
(c) Standalone diagnostic centres are single unit centres. Majority of these have small-scale of operations, and offer either pathology, basic radiology or advanced radiology services.

Exhibit 02: Indian Diagnostic Industry



Source: Company RHP

B. Based on Provision of Services:

Diagnostic entities can be broadly classified into pathology and radiology centres based on the provision of services.


- ⇒ Pathology includes examination and laboratory analysis of body fluids (blood, urine, etc.) or organs and tissues to diagnose diseases.
- \Rightarrow Radiology involves usage of imaging technologies such as X-rays, radiography, ultrasound, CT scans, MRI scans to diagnose diseases.


Segment wise breakup:

A diagnostic centre generally offers either pathology or radiology services, but few offer both. Typically, advanced radiology testing services are rendered by either secondary or tertiary care hospitals or standalone radiology centres (owned by the MD radiologist) or diagnostic chains (regional/multi-regional) as they entail heavy investments in order to obtain the best-in-class equipment, technology and specially trained professional to operate the equipment. Multi-regional diagnostic chains such as Dr. Lal Pathlabs (DLPL), Thyrocare, and SRL offer both pathology as well as radiology testing services (SRL and DLPL offer both basic and advanced radiology testing services whereas Thyrocare offers only advanced radiology service). Among regional diagnostic chains, Vijaya provides a combination of diagnostic services under an integrated services model across pathology, radiology, nuclear medicine, imaging, gastroenterology, cardiology and neurology, making it a comprehensive diagnostic centre.

According to CRISIL Research estimates, pathology testing commands a higher share (57%) of the diagnostics market. Typically, a battery of tests is prescribed under a single pathology test panel for a single patient. Though the volumes of pathology tests prescribed are greater, the price of a single pathology test is lower than a single imaging test such as an MRI or even an X-ray. The latter (radiology commands 43% market share) usually costs two to three times more than a regular pathology test.


The share of radiology testing services within diagnostic services increased from nearly 41% in FY17 to approximately 43% in FY20 at approximately 14% CAGR; CRISIL expects the share to be maintained at 43-44% in FY23E. The Indian diagnostics industry is highly fragmented given the high proportion of standalone centres and hospital-based centres, which collectively comprise 83-88% of the total market as of FY20. Diagnostic chains comprise only 12-17% as of FY20 further split into regional and multi-regional chains, of which regional chains account for the majority. However, the industry has witnessed a shift from standalone centres to diagnostic chains due to increasing trend of patients' reliance on diagnostic chains for their quality of service and unavailability of complex tests with standalone centres, not only at an overall country level but also in regional markets.





Source: Company RHP

Exhibit 04: Split of Indian Diagnostic Industry (FY20)



Source: Company RHP





Growth Drivers-Diagnostic Industry:

- Changing demographics
- Rising income levels
- Increasing health awareness
- Conducive government policies
- Changing disease profiles
- Health insurance coverage

About the Company:

Vijaya Diagnostic Centre Limited (Vijaya) is the largest integrated diagnostic chain in Southern India, by operating revenue, and also one of the fastest-growing diagnostic chain by revenue for FY20 (Source: CRISIL Report). The company offers a one-stop solution for pathology and radiology testing services to their customers through its extensive operational network, which consists of 81 diagnostic centres and 11 reference laboratories across 13 cities and towns in the states of Telangana and Andhra Pradesh and in the National Capital Region and Kolkata as on June 30, 2021. The company offers a comprehensive range of approximately 740 routine and 870 specialized pathology tests and approximately 220 basic and 320 advanced radiology tests that cover a range of specialties and clinical pathology to cytogenetics and high-end molecular diagnostic tests, and radiology tests ranging from basic echocardiograms, X-rays and ultrasounds to advanced radiology tests including Computerised Tomography (CT) scans, Magnetic Resonance Imaging (MRI) scans, Single Photon Emission Computed Tomography (SPECT) and advanced Positron Emission Tomography CT (PET CT). The company has implemented a 'hub and spoke' model, whereby specimens are collected across multiple locations within a catchment area or a region for delivery to their reference laboratories for diagnostic testing. As of June 30, 2021, all of the laboratories hold National Accreditation Board for Testing and Calibration Laboratories (NABL) and three of its diagnostic centres hold Patient Safety & Quality of Care (NABH) accreditations.

Competitive Strengths:

(i) Largest and fastest growing diagnostic chain with dominant position in South India: The company is the largest integrated diagnostic chain in southern India, by operating revenue, and also one of the fastest-growing diagnostic chain by revenue for FY20 (Source: CRISIL Report). It has an extensive operational network consisting of 81 diagnostic centres including a flagship centre located at Hyderabad, and 11 co-located reference laboratories, including a national reference laboratory at the flagship diagnostic centre, across 13 cities and towns in the states of Telangana and Andhra Pradesh and in National Capital Region and Kolkata, as of June 30, 2021. For the three months ended June 30, 2021, the company derived 87.18% and 8.73% of the revenue from operations from Telangana and Andhra Pradesh, respectively. For FY21, 86.21% and 9.99% of its revenue from operations came in from Telangana and Andhra Pradesh, respectively.

(ii) Integrated diagnostics provider that offers One-Stop solution at affordable price: Vijaya offers a comprehensive range of approximately 1,610 pathology tests, which are organised into approximately 740 routine tests and 870 specialized tests, as well as approximately 220 basic and 320 advanced radiology tests that cover a range of specialties and disciplines, as of June 30, 2021. The company currently also offers RT-PCR testing and/or CT scan for Covid-19 diagnosis across 33 diagnostic centres in 11 cities and towns and Covid-19 vaccination services at its Kolkata and Gurugram diagnostic centres. Vijaya has been one of the earliest private diagnostic service providers to be approved for Covid RT-PCR testing by ICMR in Andhra Pradesh and Telangana (Source: List of Private Laboratories to test Covid-19 published on March 24, 2020).

(iii) Long track record of consistent profitable growth, strong cash generations: For the three months ended June 30, 2021, the company recorded a total income of Rs1,259.70mn. During the same period, the operating revenue per test was Rs562.31 and operating profit before depreciation, interest and tax (OPBDIT) per test was Rs260.59; operating revenue per customer stood at Rs1,298.96 and OPBDIT per customer at Rs601.39. For FY21, the total income came in at Rs3,885.93mn. The company has an attractive financial profile which is evident by negative working capital and high cash flow generation leading to a strong net cash position. For FY20, the average test per customer ratio was 2.8 (followed by 2.5 for DLPL), operating revenue per customer was Rs1,214 and OPBDIT per customer was Rs475, all of which are higher as compared to its listed peers as per the CRISIL Report.





Strategies:


(i) Leverage existing presence by focusing on setting up spoke centres: Vijaya will continue to focus on expanding the network through setting up spokes and select hub centres in existing catchment areas. In addition, they would also be adding reference laboratories in their existing core geographies. The total number of its spokes have grown from 45 as of April 1, 2019 to 60 as of June 30, 2021. The company further plans to set up additional diagnostic centres in Telangana and Andhra Pradesh and also increase home collection services in core geographies to reach out to more customers.

(ii) Provide customer centric services and offerings: The company intends to widen the diagnostic services by offering additional preventive and wellness services and through, among other things, the adoption of new, cutting-edge diagnostic testing technology. It also intends to offer more preventive and wellness packages, preventive healthcare screening and chronic and lifestyle disease management services to individual and corporate customers, given the increasing health awareness of, and concomitant increase in, chronic and lifestyle diseases in India. Leveraging the current needs of their customer base, Vijaya offers RT-PCR testing for Covid-19 diagnosis across 25 diagnostic centres in nine cities and towns and Covid-19 vaccination services at its diagnostic centres located at Kolkata, West Bengal and Gurugram, Haryana, and intend to grow these test offerings to few other diagnostic centres/hubs.


(iii) Expand in adjacent geographies: The company intends to establish its presence in adjacent geographies of Telangana and Andhra Pradesh and expand in concentric circles. They have identified key cities and towns that the company believes are underserved, and where the brand is well-regarded. A wider geographic reach would expand the customer base as well as improve the profitability by allowing the company to better leverage its infrastructure.

Financials:

For the three months ended June 30, 2021 and FY21, the company derived 95.91% and 96.2% of its revenue from operations from their core geographies, Hyderabad and rest of Telangana and Andhra Pradesh, respectively. During three months ended June 30, 2021, the company conducted approximately 1.96 million pathology tests and 0.22 million radiology tests for approximately 0.94 million customers. During FY20, the tests per customer visit was 2.83, operating revenue per customer was Rs1,213.72 and operating revenue per test was Rs428.14, all of which are higher as compared to its listed regional peers as per the CRISIL Report. For the three months ended June 30, 2021, FY21 and FY20, the sales came in at Rs1227mn, Rs3767mn and Rs3388mn respectively and PAT stood at Rs333mn, Rs849mn and Rs625mn respectively. For the three months ended June 30, 2021, FY21, FY20 and FY19 the cash generated from operations came in at Rs509.45mn,Rs1,296.43mn,Rs1,061.12mn and Rs905.27mn resp. The Ebitda margins came in at 39.1%, 44.1% and 46.3% for FY20, FY21 and 3 months ending June, 2021 respectively.



Source: Company RHP, Progressive Research







Exhibit 7: Comparison of OPBDIT (FY20)

Exhibit 5: Financial Snapshot



Source: Company RHP

Source: Company RHP





IPO UPDATE

Vijaya Diagnostic Centre Limited

Risks & Concerns:

- Business and prospects may be adversely affected if the company is unable to maintain and grow its brand name and brand image.
- The business, financial condition and results of operations may be adversely affected by global health epidemics, including the recent Covid-19 outbreak, and the continuing effect of the same cannot be predicted.
- Any interruptions at the flagship centre and other diagnostic centres may affect the company's ability to process diagnostic tests, which in turn may adversely affect its business, results of operations and financial condition.
- Major operations are concentrated in South India, and any loss of business in such region could have an adverse effect on the business, results of operations and financial condition.
- Dependency on third-parties to provide the company with testing equipment and reagents, and any failure to continue to do so or recall of existing testing equipment and reagents could adversely affect the business, results of operations and financial condition.

Outlook and Recommendations:

Vijaya is an integrated diagnostic player that offers a combination of services across pathology, basic radiology; having its dominant position based out of Southern India which attributes to major operational revenues. The company adopts a customer centric approach that enables them to deliver value added services such as home collection of specimens, house calls and various delivery/access modes for test reports. The company has plans in place to leverage the existing networks and additionally set up further diagnostic centres in Telangana and Andhra Pradesh in the near future. Considering the highly competitive, fragmented and underserved diagnostic industry, the company would lay its focus on expanding the network base, add reference laboratories in its exiting core geographies. On the financials front, the company has consistently improved its Ebitda margins for FY20, FY21 and 3 months ending June, 2021. Additionally, the company has reported the highest gross margins (62%) for FY20. The company has the highest brand recall recognition, high share of walk-in customers and sticky individual customer revenue. Based on FY21 earnings, the company is trading at a P/E of 63.77x. **The document is for information purpose. We do not have any rating on the IPO and keep it at the discretion of the investors with regard to investment in the IPO.**



PRØGRESSIVE our Progress Our Priority...



Equities | Derivatives | Commodities | Currency | Depository | Mutual Funds | NBFC | e-Broking

IPO UPDATE Vijaya Diagnostic Centre Limited

DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products. PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time. PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report-:

PSBPL or its associates financial interest in the subject company: NO

Research Analyst (s) or his/her relative's financial interest in the subject company: NO

PSBPL or its associates and Research Analyst or his/her relative's does not have any material

conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company. · PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.

The research Analyst has served as officer, director or employee of the subject company: NO

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such juris diction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party. without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address: Progressive Share Brokers Pvt. Ltd, 122-124, Laxmi Plaza, Laxmi Indl Estate, New Link Rd, Andheri West, Mumbai-400053: www.progressiveshares.com | research@progressiveshares.com

Compliance Officer: Mr. Shyam Agrawal, Email Id: compliance@progressiveshares.com, Contact No :022-40777500

